NCT05361395 2026-03-03
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Amgen
Phase 1 Active not recruiting
Clinical Trials
3 trialsNCT03319940 2025-11-19
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
Amgen
Phase 1 Active not recruiting
NCT06064500 2025-03-10
Tarlatamab (AMG 757) Expanded Access Protocol for Advanced Small Cell Lung Cancer
Amgen
Approved for marketing